Innovative New Drugs Emerge to Address Unmet Needs in High‑Demand Rare Diseases

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a recommendation for approval of five new medicines at its April 2026 meeting, including Sanofi's multiple sclerosis therapy Cenrifki (generic name tolebrutinib). The recommendation offers innovative treatment options for patients with non‑relapsing secondary progressive multiple sclerosis (nrSPMS) and familial chylomicronemia syndrome (FCS), conditions that previously lacked therapies. Notably, Arrowhead's Redemplo (generic name plozasiran) and Novartis's Itvisma (generic name onasemnogene abeparvovec) were also included, drawing particular attention. Having cleared the regulatory hurdle, these products are expected to receive final marketing authorization from the European Commission (EC) and pursue market entry.

Differentiated Therapeutic Efficacy Demonstrated in Phase III Trials

Sanofi's Cenrifki is a BTK inhibitor capable of crossing the blood‑brain barrier (BBB). In the Phase III HERCULES trial, it reduced the risk of 6‑month confirmed disability progression (CDP) by 31% versus placebo (hazard ratio 0.69). Arrowhead's Redemplo is an siRNA therapy targeting APOC3; in the Phase III PALISADE study it achieved up to an 80% reduction in fasting triglyceride levels, demonstrating overwhelming efficacy. Novartis's Itvisma also showed a statistically significant improvement of 1.88 points on the Hammersmith Functional Motor Scale Expanded (HFMSE) versus placebo in the Phase III STEER trial, establishing its role as an intrathecal gene therapy. Such robust clinical data have been decisive in securing approval from the stringent European regulatory authorities.

Biosimilars and Generics Enter the Market in Response to Blockbuster Patent Expiries

In addition to the new drugs, a number of biosimilars and generics were included in the recommendation, supporting cost containment for European health systems and improving patient access. Intas's Rexatilux (generic name ranibizumab) is a biosimilar of the ophthalmic therapy Lucentis and is expected to stimulate price competition in the market. Viatris's Palbociclib Viatris, the first generic of the breast‑cancer treatment Ibrance, also secured a recommendation, which should reduce out‑of‑pocket costs for patients. The entry of these follow‑on products creates pricing pressure on originator companies and acts as a catalyst for new pipeline development.

Reimbursement Barriers and Strategic Shift Following Soleno’s Viokat Withdrawal

For new medicines to establish a foothold in Europe, they must overcome pricing negotiations with national health authorities and achieve reimbursement listing. The ultra‑expensive gene therapies Itvisma and Redemplo are expected to face lengthy timelines for national formulary inclusion due to their high price tags. Meanwhile, Soleno voluntarily withdrew its European marketing authorization application for Viokat, a therapy for Prader‑Willi syndrome (PWS) (generic name diazoxide choline). This withdrawal is interpreted as a strategic decision aimed at securing commercial partnerships and strengthening pricing leverage in the European market, rather than being driven by safety concerns.